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Abstract
Introduction: This study examined the short- and long-term effects of a quality improvement collaborative on
patient outcomes, professional performance, and structural aspects of chronic care management of type 2 diabetes
in an integrated care setting.
Methods: Controlled pre- and post-intervention study assessing patient outcomes (hemoglobin A1c, cholesterol,
blood pressure, weight, blood lipid levels, and smoking status), professional performance (guideline adherence),
and structural aspects of chronic care management from baseline up to 24 months. Analyses were based on 1,861
patients with diabetes in six intervention and nine control regions representing 37 general practices and 13
outpatient clinics.
Results: Modest but significant improvement was seen in mean systolic blood pressure (decrease by 4.0 mm Hg versus
1.6 mm Hg) and mean high density lipoprotein levels (increase by 0.12 versus 0.03 points) at two-year follow up.
Positive but insignificant differences were found in hemoglobin A1c (0.3%), cholesterol, and blood lipid levels. The
intervention group showed significant improvement in the percentage of patients receiving advice and instruction to
examine feet, and smaller reductions in the percentage of patients receiving instruction to monitor blood glucose and
visiting a dietician annually. Structural aspects of self-management and decision support also improved significantly.
Conclusions: At a time of heightened national attention toward diabetes care, our results demonstrate a modest
benefit of participation in a multi-institutional quality improvement collaborative focusing on integrated, patient-
centered care. The effects persisted for at least 12 months after the intervention was completed.
Trial number: http://clinicaltrials.gov Identifier: NCT 00160017
Introduction
Good clinical care for patients with type 2 diabetes
requires increasingly complicated drug regimens, close
monitoring, and ongoing self-management support [1,2].
For best results, diabetes care also requires effective brid-
ging of primary and specialist care with providers crossing
practice and organizational boundaries [3]. Cooperation
between hospitals and general practices that focus on inte-
grated, patient-centered care is vital [4,5].
Despite a wealth of evidence and clinical practice
guidelines, treatment gaps in diabetes care are visible
when ‘best practice’ encompassing chronic care manage-
ment, professional performance, and patient outcomes is
compared with usual care [6,7]. Diabetes is a complex
multi-systemic chronic disease and is difficult to fit into
a healthcare delivery system designed to deal with acute
and episodic illness. Despite reports of interventions
designed to improve diabetes care, we do not know
which strategies are most effective [8,9]. In a recent
meta-analysis, team changes and case management
showed the most robust improvements, although esti-
mates of effectiveness of other specific quality improve-
ment strategies may be limited by difficulty in
* Correspondence: loesschouten@xs4all.nl
1Dutch Institute for Healthcare Improvement, P.O. Box 20064, 3502 LB
Utrecht, The Netherlands
Full list of author information is available at the end of the article
Schouten et al. Implementation Science 2010, 5:94
http://www.implementationscience.com/content/5/1/94
Implementation
Science
© 2010 Schouten et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
classifying complex interventions, too few studies, and
publication bias [10]. We hypothesized that a multifa-
ceted implementation approach emphasizing collabora-
tive learning and exchange of insights and support
among a set of healthcare organizations, like a quality
improvement collaborative (QIC), may be helpful to
improve diabetes management and reduce risks of com-
plications. QICs bring together a group of healthcare
providers from different sites who meet periodically to
learn, to exchange ideas and quality methods, and to
share experiences with making changes. The aim of a
QIC is to close the gap between potential and actual
performance by testing and implementing changes
quickly across many organizations [11]. QICs are fre-
quently used to improve care systems in multiprofes-
sional settings [12]. The strength of QICs is apparently
the relatively efficient use of experts and peers, as well
as exchange of evidence and best practices, to guide
multiprofessional teams in improvement. However, the
widespread acceptance and use of QICs are not based
on a systematic assessment of effectiveness [13]. A
recent systematic review of QICs shows varying success
in achieving collaborative goals; none of the included
studies provided information on the sustainability of
effect [14].
To improve chronic care in an integrated care setting,
a national QIC was set up to encourage high-quality,
integrated diabetes care in the Netherlands. This volun-
tary QIC was designed to bring together and support
multiprofessional diabetes teams from primary care and
outpatient hospital clinics in applying evidence-based
clinical practice. We hypothesized that this intervention
could facilitate and support multiprofessional teamwork,
integration of primary and specialist care to improve
care systems, professional performance (guideline adher-
ence), and patient outcomes.
The aim of our study was to assess the impact of this
multi-institutional QIC by measuring patient outcomes,
professional performance measures, and structural aspects
of chronic care management. Because little is known
about the impact and sustainability of QICs, the results
are also meant to give insight into the short- and long-
term effectiveness of this QIC in diabetes care compared
to usual care.
Methods
Design
In a controlled, pre/post study design, the study
included 15 sites representing multiprofessional provider
teams from outpatient hospital clinics and general prac-
tices. We examined diabetes care for 12 months before
(2004), 12 months during (2005), and 12 months after
(2006) the QIC intervention.
Participants
Recruitment of sites
In 2004, the Dutch Institute of Healthcare Improvement
sent letters inviting diabetes provider teams in outpatient
clinics and general practices nationwide to participate in a
QIC in 2005. Two invitational meetings informed teams
about the goals and structure of the project. The provider
teams were asked to participate with at least one hospital
and two or three collaborating general practices in their
region so that they could form a multiprofessional
improvement team. The teams consisted of medical, nur-
sing, and allied health professionals from regional outpati-
ent clinics and general practices. Eight geographically
distinct sites volunteered to participate, and each had to
pay a fee of €23,750 to cover project management costs.
One site dropped out at the start of the project. The provi-
der teams of six sites volunteered for our evaluation study
(one site declined to provide evaluation data).
For each intervention site, we identified control sites
with a provider team delivering usual care. The potential
control and intervention sites were matched for type of
site (hospital, university medical center, or general prac-
tice), location (rural or urban), size (number of beds),
and teaching affiliation (yes/no). Nine sites agreed to
participate in our control group.
Recruitment of patients
All provider teams were asked to hand out questionnaires
and written consent forms for three to six weeks to
patients visiting the clinic or practice. Their own physi-
cians invited the patients to participate; patients were eligi-
ble if they were adult (older than18 years), had type 2
diabetes, were not pregnant, had a life expectancy longer
than one year, and could complete a questionnaire in
Dutch. In each survey, patients were asked permission for
their medical records to be examined in the study. When
patient recruitment stagnated, we extended the inclusion
period to 10 weeks and encouraged physicians to also
include patients for medical record examination only.
Sample size
Power calculations for the sites were based on changes in
mean hemoglobin A1c (HbA1c; our primary outcome
measure). Assuming an expected difference of 0.4
between intervention and control sites in mean HbA1c,
with a standard deviation of measurement of 1.5, alpha =
0.05, beta = 0.20, and an intracluster correlation coeffi-
cient (rho) = 0.02 [15], an average of 75 patients per site,
or a total of 1,125 patients, were required for the study.
Quality improvement intervention
The intervention sites were requested to form a multidis-
ciplinary improvement team composed of medical, nur-
sing, and allied health professionals from the outpatient
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clinic and general practices in the region. During the
project, four national meetings (including one kick-off
meeting) were organized to inform the participating
teams about the best available evidence concerning dia-
betes (based on national and international guidelines),
best practices and the best way to implement it. To
achieve improvements, the teams were directed and sup-
ported to: change professional performance and the orga-
nization of care; introduce self-management of patients;
and introduce a system to register clinical parameters.
However, each team was free to focus on specific quality
improvement interventions depending on service-specific
routines or bottlenecks. Specific team targets included:
the development of local protocols and shared care
agreements between professionals (n = 5); development
of local protocols focusing on the prevention of severe
complications (n = 4); the communication of patient
information (on the disease, its complications, the neces-
sity of strict control, and patient partnering) (n = 2); and
the monitoring of clinical indicators (n = 6). Each confer-
ence included sessions that focused on specific aspects of
diabetes care, e.g., importance of annual follow up, targets
for glycemic and cardiovascular risk control and therapy
according to a step-up regimen to achieve those targets,
interventions to enhance self management and lifestyle
modifications, patient education and cooperation, and
access to consulting services from, e.g., endocrinologists
and diabetes educators for patients not responding to
treatment or those whose diabetes is difficult to manage.
A systematic approach was encouraged: the teams had to
choose clear and measurable improvement aims, collect
data, and plan interventions to improve care. The teams
were supported by a national expert team that specializes
in diabetes. Collaboration and sharing between partici-
pants was explicitly encouraged. Table 1 gives a sche-
matic overview.
Effect parameters
Given the diversity in improvement topics of the sites, the
aim of this study was to measure the possible impact of
the QIC on a wide variety of patient outcomes, profes-
sional performance, or structural aspects of diabetes care.
We collected information on effect parameters (based on
clinical practice guidelines) [16-19] at baseline, one year
and two years follow up. We extracted patient outcomes
and professional performance data from medical records
and patient survey, as well as data about structural aspects
of chronic care management from provider surveys.
Patient outcomes (nine effect parameters)
To determine the collaborative’s impact on patient out-
comes, we assessed individual patient levels of HbA1c,
systolic blood pressure, diastolic blood pressure, total
cholesterol, high density lipoprotein (HDL), low density
lipoprotein (LDL), body mass index (BMI), and triglycer-
ides. On-site abstractors (nurses and practice assistants),
whom we recruited, obtained patient outcome data from
medical records. We provided them with detailed verbal
and written instructions about the rules for scoring the
biomedical items in the abstraction instrument. All
available values over three years were obtained and
afterwards a mean per patient per year was calculated.
Data abstractors were blinded to whether the region was
an intervention or control site. To assess the reliability
of the data extraction, we asked the on-site abstractors
to perform a re-extraction on a random subsample of
10% of the medical records on each site (intraobserver
reliability 97%). Smoking status was assessed by patient
survey.
Professional performance (19 effect parameters)
Our process measures representing good clinical prac-
tice were the appropriate assessment of glycemic and
cardiovascular risk control.
Based on the medical record data abstraction (as
already described), we determined whether at least one
measurement of HbA1c, blood pressure, total choles-
terol, HDL cholesterol, LDL cholesterol, triglycerides,
creatinine, urine albumin, and BMI per patient per year
were performed. Data about annually foot and eye
examinations, consultations with dieticians and podia-
trists, and counseling (advice and instruction to monitor
blood sugar, healthy diet, exercise, and smoking cessa-
tion) were obtained by patient questionnaire because
medical records often do not include such data [20]. We
determined binary scores for the professional perfor-
mance measures, i.e., the patient either passed or failed
the indicator (yes or no annually, measurement, exami-
nation, consultation, or instruction and advice) during
baseline or one and two years follow up periods. The
baseline questionnaire also requested demographics
such as age, gender, and duration of diabetes; and asked
about the following co-morbidities: history of foot
ulcers, cardiovascular disease, stroke, renal disease, and
retinopathy.
Structural aspects of chronic care management (four
effect parameters)
We used four of the six components of the Assessment
of Chronic Illness Care survey http://www.improving-
chroniccare.org [21-23] to assess structural aspects of
chronic care management at each outpatient hospital
clinic and general practice. These aspects represented
the focus of improvement in our QIC intervention: self-
management support, decision support, delivery system
design, and clinical information systems. The provider
teams were asked to complete this 19-item question-
naire three times (at baseline, after measurement, and at
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follow up). The respondents rated the degree to which
each component (e.g., use of evidence-based guidelines,
involvement of specialists in improving primary care,
use of reminders and patient treatment plans, addressing
concerns of patients and families, partnerships with
community organizations, and use of information
system to monitor performance, quality improvement,
and to identify groups of patients needing additional
care) was implemented within their diabetes care sys-
tem, on a scale ranging from 0 (not at all) to 11 (fully).
We computed subscale scores for each section and an
overall score. A section score summed the values for all
Table 1 Components of the quality improvement collaborative intervention
Preparation phase Context and Topic selection
In the Netherlands, access to care is easily available and almost fully reimbursable. Although the care for people with
diabetes type 2 was mainly concentrated in primary care in the last decades, people with diabetes now receive care in
primary, secondary or tertiary level care settings, The integrated care strategy intends to develop a model of care that will
provide an appropriate structure to deliver the full range of health, personal, and social services and initiatives to improve
the organization, management, and integration or coordination of primary generalist care and secondary specialist care
services for diabetes (including diabetes specialist nurses, dieticians, podiatrists, and specialist support). Guidelines on care
and prevention are amply available but not fully implemented. As part of an alliance between the Dutch Institute for
Healthcare Improvement and the College of Health Insurances to improve chronic care in an integrated care setting, a
national quality improvement collaborative (QIC) based on the Breakthrough Series http://www.ihi.org was set up to
encourage high quality in integrated diabetes care in the Netherlands. This voluntary quality improvement strategy was
designed to bring together and support multiprofessional diabetes teams from primary care and outpatient hospital
clinics.
Expert meeting
In the preparation phase, an expert meeting of 30 national diabetes experts including general practitioners, diabetologists,
specialized diabetes nurses, dieticians, podiatrists, members of the Dutch Diabetes Federation, and other patient
organizations was organized. The purpose was to gain insight into current diabetes care barriers and facilitators. The
experts listed 12 barriers and facilitators on the patient, professional, and organizational levels.
Expert panel and change concepts
Following the expert meeting, an expert panel representing five national diabetes experts and two quality improvement
experts was installed to facilitate and support the participating provider teams. The expert panel prepared a package of
ideas (change concepts) for closing the gap between best and actual practice. The package was based on national and
international diabetes guidelines, field surveys, personal experience, and the barriers and facilitators mentioned in the
expert meeting.
Recruitment of
participants
Letters of invitation
In 2004, letters of invitation were sent to invite diabetes provider teams in outpatient hospital clinics and general practices
nationwide to participate in a diabetes QIC on in 2005.
Invitational meeting
In addition, two invitational meetings were organized to inform teams about the goals and structure of the project. The
participating teams each had to pay a fee of €23.750 Euro to cover project management costs.
Start Kick-off
Before the kick-off meeting, the participating multidisciplinary provider teams were asked to collect some baseline data
and to describe the current diabetes practice to identify ‘performance gaps’ in their practice. In the national kick-off
meeting, the teams were provided with materials and information (package of change). The kick-off session provided
information about the change package and quality improvement techniques. The topics included setting aims, the use of
measurement and small, incremental tests of change.
Execution phase Learning Sessions
The teams attended three learning sessions about the change package, quality improvement methods, and reporting their
experiences, changes, and results for their targets.
Plan Do Study Act (PDSA) cycles
Between meetings, the team members recruited other providers from their respective organizations (participating hospitals
and general practices) to implement selected changes and measure progress in their own organizations. They used a
PDSA change testing method to plan, implement, and evaluate many small changes in quick succession (the rapid cycle
improvement method). The expert panel supported the teams by means site visits, conference calls, e-mail ‘listserv’
discussion groups, and feedback.
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section items (e.g., self-management support), which was
divided by the number of items within that section. The
overall score was derived linearly: the average scores of
each section were summed, and then divided by the
number of sections.
Statistical analysis
For both patient outcomes and professional performance
measures, differences between intervention and control
sites were assessed with a mixed logistic model for
dichotomous outcomes, and a mixed regression model
for continuous outcomes. In each model, the baseline
score was entered as a covariate for correcting possible
baseline differences between the intervention and con-
trol group at the start of the trial. Analyses were per-
formed separately for short term (one year follow up)
and long term (two years follow up) and differences
were assessed across sites. Patient clustering within
clinics and practices was accounted for. All multilevel
analyses were performed with the MIXED and GLIM-
MIX procedures in SAS (SAS version 9.1.3, SAS Insti-
tute, Cary, North Carolina). Missing outcomes were not
replaced. P values less than 0.05 were considered statis-
tically significant. In Tables 2, 3, and 4, we present
unadjusted performance scores, but the calculated sig-
nificance levels are based on the abovementioned multi-
level analysis.
For assessing the impact on structural aspects for
chronic care management, we performed an analysis of
covariance (ANCOVA) using short-term (one year
follow up) and long-term (two years follow up) out-
comes, and baseline measurement as a covariate in the
model.
Results
Study sites and patients
The 15 participating sites (six intervention and nine
control sites) represented multiprofessional provider
teams from 13 outpatient clinics (47 internists) and 37
general practices (42 general practitioners). Most teams
had five or six members, including an internist, one or
more general practitioners, a diabetes nurse, and some-
times a dietician or physiotherapist. Four intervention
sites and six control sites had training affiliations. One
intervention site and two control sites had university
hospital links.
Table 2 shows the study sites and patient characteristics
at baseline. Altogether, we collected information from
medical records for 1,861 patients (i.e., 607 intervention
patients and 1,254 control patients). A total of 1,630
patients completed the survey (583 intervention patients
and 1,047 control patients). At one and two years follow
up, 1,368 (84%) and 1,206 (74%) of these patients com-
pleted the survey, respectively. The mean number of
patients per center was 124 (SD 44). Including only
patients that provided both medical record and survey
data in the analyses (n = 1,630) did not change the results.
The average patient was 66 years old, and 53% of the
patients were men. Patients were diagnosed with dia-
betes 13 years previously on average. Approximately
Table 2 Site and patient characteristics at baseline
Site and patient characteristics at baseline Intervention Group Control Group
Site characteristics
Number of sites participating in QIC 7 0
Number of sites participating in evaluation study 6 9
Number of hospitals 5 8
Number of general practices 12 25
Number of patients 607 1254
Age in years (SD) 66 (12.1) 67 (11.2)
Gender, percentage of men 54.8 52.2
Years since diagnosis (SD) 13.5 (10.1) 13.3 (9.1)
Complications (in percentages)
History of: Foot ulcer 11.6 13.4
Cardiovascular disease 22.3 23.3
Stroke 6.5 8.1
Renal disease 5.9 5.5
Retinopathy 10.2 9.1
Patient characteristics (survey n = 1,630)
*P = 0.01.
QIC = Quality improvement collaborative.
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Table 3 Outcome measures: patient outcomes
Intermediate outcome
indicators
Baseline Short term
(one year follow up)
Long term
(two years follow up)
Medical record
(n = 1,861)
Intervention (SD) Control (SD) Intervention (SD) Control (SD) Intervention (SD) Control (SD)
Mean HbA1C mmol/l (SD) 7.5 (1.3) 7.5 (1.2) 7.3 (1.2) 7.4 (1.2) 7.2 (1.2) 7.2 (1.2)
Mean systolic blood pressure
mm Hg (SD)
143.3 (19.2) 143.4 (17.2) 141.6 (18.1) 141.6 (16.5) 139.3 (17.4) 141.8* (16.5)
Mean diastolic blood pressure
mm Hg (SD)
80.4 (8.8) 80.2 (8.9) 79.3 (8.8) 78.9 (8.6) 78.5 (9.1) 78.7 (8.6)
Mean cholesterol 4.9 (0.9) 4.9 (1.1) 4.6 (0.9) 4.6 (0.9) 4.4 (0.9) 4.5 (0.9)
Mean HDL 1.3 (0.4) 1.3 (0.4) 1.3 (0.4) 1.3 (0.4) 1.4 (0.4) 1.3** (0.4)
Mean LDL 2.8 (0.9) 2.9 (0.9) 2.7 (0.9) 2.6 (2.0) 2.5 (0.8) 2.6 (2.0)
Mean BMI 29.7 (5.6) 29.6 (4.9) 29.7 (5.3) 29.5 (4.9) 29.9 (5.5) 29.7 (4.9)
Mean triglycerides 1.9 (1.1) 1.9 (1.3) 1.8 (1.1) 1.8 (1.1) 1.7 (1.1) 1.8 (1.1)
Nonsmokers (in percentages) 83.5 83.3 84.5 84.9 83.7 85.7
*p < 0.05; **p < 0.001.
BMI, Body mass index; HDL = high density lipoprotein; LDL = low density lipoprotein.
Patient outcome scores are presented as unadjusted.
P value is for testing the difference between intervention and control arm at baseline and one year follow up respectively baseline and two yearsfollow up using
a mixed logistic model for dichotomous outcomes, and a mixed regression model for continuous outcomes adjusting for baseline scores.
Table 4 Process measures: professional performance
Intermediate outcome indicators
(percentage of patients)
Baseline Short term (one year follow up) Long term (two years follow up)
Intervention Control Intervention Control Intervention Control
Medical record (n = 1,861)
HbA1c checked within 12 months 82.4 91.5* 95.7 95.4 93.7 93.2
Blood pressure checked within 12 months 79.4 89.7*** 89.9 93.1 88.6 91.1
Cholesterol checked within 12 months 69.4 80.1 83.2 84.3 82.2 83.4
Creatinine test within 12 months 72.9 82.1 87.8 86.9 85.5 86.8
Urine test (microalbuminuria) within 12 months 37.9 49.9 45.1 56.6 45.3 61.0
Weighed within12 months 68.7 78.7 81.2 84.8 74.5 83.5
Body mass index calculated within 12 months 22.7 33.4 43.7 39.1 41.8 43.7
Survey (n = 1,630)
Eye examination within 12 months 85.2 90.9* 88.3 90.8 90.1 92.5
Foot examination within 12 months 77.5 77.8 82.7 82.7 83.0 85.2
Visit to dietician (survey) within 12 months 29.5 23.8* 15.8 12.8 17.8 9.9**
Visit to podotherapist (survey) within12 months 27.7 26.8 20.6 26.8 28.0 27.3
Received advice to self-monitor blood glucuose 72.4 66.3 69.7 64.8 68.7 65.7
Received instruction to monitor blood glucose 74.2 68.2 59.5 52.4* 61.7 55.8*
Received advice to examine feet 76.4 72.1 77.2 68.5* 75.2 69.4*
Received instruction to examine feet 64.6 59.2 65.9 56.3* 66.0 59.5*
Received advice not to gain weight 88.4 89.1 70.9 71.0 68.4 67.1
Received advice for healthful diet 94.9 93.7 75.1 71.6 72.4 67.6
Received advice for regular exercise 93.6 91.1 82.9 79.6 78.6 76.5
Received advice to stop smoking 74.6 75.7 77.9 73.0 64.6 65.8
*p < 0.05; **p < 0.01; ***p < 0.001.
Performance scores are presented as unadjusted.
P value is for testing the difference between intervention and control arm at baseline and one year follow up, andbaseline and two years follow up, respectively,
using a mixed logistic model for dichotomous outcomes, and a mixed regression model for continuous outcomes adjusting for baseline scores.
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22% of the patients had a history of cardiovascular dis-
ease. Participating and control patients did not differ
significantly in socioeconomic characteristics (except
ethnicity), history of complications, or outcome mea-
sures. The proportion of patients of Hindustani, Moroc-
can, or Surinamese origin was greater in the control
group, mainly due to the extra number of hospitals in
an urban region. Patient group analysis with and with-
out these hospitals did not change the findings for other
baseline processes and outcome measures.
Patient outcomes
Table 3 depicts the performance changes of the patient
outcome indicators for the two arms from baseline to the
follow-up period. No short-term significant changes were
seen between intervention and control group at one-year
follow up. At two-year follow up, the mean systolic blood
pressure decreased significantly by 4.0 mm Hg (from
143.3 mm Hg to 139.3 mm Hg) in the intervention group
compared with 1.6 mm Hg (from 143.3 mm Hg to 141.8
mm Hg) in the control group. We also observed a statis-
tically significant increase in mean HDL levels in the
intervention group of 0.12 points compared to 0.03
points in the control group at follow up. Mean HbA1c
levels diminished by 0.3% in both groups. Differences for
HbA1c, blood lipids, and cholesterol levels between inter-
vention and control group were small and insignificant.
The intervention effectiveness (slope of improvement)
did not differ between outpatient hospital clinics and
general practices.
Professional performance
Table 4 compares the scores of the participating and
control provider teams for professional performance at
baseline and follow up. Baseline adherence rates to
annual examination for HbA1c, blood pressure, and eye
examination were significantly higher at the control
sites. The baseline rate to annual visit to a dietician was
higher at the intervention group.
Some significant changes were seen between interven-
tion and control group at one and two years follow up.
The intervention group showed a modest but significant
short-term improvement in the percentage of patients
receiving advice and instruction to examine feet and
smaller reductions in the percentage of patients receiv-
ing instruction to monitor blood glucose. These effects
persisted for at least 12 months. Less worsening was
seen in the percentage of patients visiting a dietician
annually at two years follow up (long term). Both inter-
vention and control sites slightly increased the number
of patients with annual eye and foot examinations. Sev-
eral patient information scores (received advice about...)
declined over the years in both arms.
Structural aspects of chronic care management
Thirty-five physicians from outpatient clinics and gen-
eral practices (response rate 70%) provided information
about structural aspects of chronic care management.
Intervention group scores for self-management support
and decision support differed significantly between
intervention and control groups at one respectively two
years follow up. Intervention group scores improved by
a single point (1.0) at both one year and two years fol-
low up; control group scores diminished by 0.5 point
(Table 5). Scores for delivery system design and clinical
information systems remained unchanged during the
measurement periods.
Discussion
Our study showed modest but significant long-term
effects in mean systolic blood pressure, HDL levels,
scores for decision support, and less worsening in the
percentage of patients visiting a dietician annually. Short
term, the percentage of patients receiving advice and
instruction to examine feet and scores for self-manage-
ment improved significantly and less worsening was
seen in the percentage of patients receiving instruction
to monitor blood glucose. These changes persisted for
at least 12 months after the intervention completed. We
also found encouraging results on cardiovascular disease
risk control at two years follow up (i.e. significant
improvement of systolic blood pressure and HDL levels
at two years follow up) [24]. The declining patient infor-
mation scores (received advice about...) are intriguing.
Perhaps some patient information is not provided
repeatedly every year. Although we cannot exclude that
patients may not remember having received an update,
implicating some recall bias.
The baseline figures collected in our study are in line
with the national figures in other studies [15] and our
findings are consistent with the outcomes of a systema-
tic review of QICs [14]. The results also reflect findings
from other uncontrolled QIC intervention studies
[25,26] and intervention studies in diabetes care [27]
that show that most improvement projects produce
small to modest improvement. The 0.3% difference in
mean HbA1c levels in both arms is compatible with a
recent meta-regression analysis [10].
Examining within group comparisons (difference in dif-
ferences across intervention and control sites), the mean
change (Δ) in proportion of patients with HbA1c, blood
pressure, cholesterol, creatinine, and BMI checked
annually increased significantly over the years at the inter-
vention sites compared to the control sites (10 to 21% ver-
sus 1.5 to 6%; data not shown). Although some key effect
parameters clearly improved in the intervention group, the
observed difference between intervention and control sites
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(correcting for baseline scores) was modest. There are sev-
eral possible reasons. First, significant baseline differences
did exist for adherence rates for annual examination of
HbA1c, blood pressure, eye examinations, and visits to a
dietician. Given the baseline differences, both groups ulti-
mately performed to an equivalent degree. This suggests
that especially low-scoring sites were engaged to partici-
pate in the QIC, using the intervention to improve their
quality of care. It also may suggest that lower baseline sta-
tus facilitated greater improvement in professional perfor-
mance at participating sites. Second, for some effect
measures, the quality of care might be reasonably good,
leading to a ceiling effect at the clinics, with little room for
improvement. Third, changing diabetes management may
be complex and improving patient care, particularly in a
QIC context for 12 months, may generate insufficient
robustness to overcome difficult organizational bottle-
necks or routines [12]. Perhaps the critical mass of data
and sites needed to cultivate useful exchanges of ideas,
experience, and learning in the QIC was not reached
[13,28]. Fourth, the specific team or organizational charac-
teristics of the sites may have influenced the effectiveness
of the QIC [12,13,28]. Although all the intervention sites
improved to a certain degree, the specific interventions
and the results among sites were heterogeneous. This is
no surprise, given the many factors contributing to suc-
cessful improvement and the likelihood that commitment
to improvements, motivations, and mechanisms vary
among sites [11,28,29]. We assessed key characteristics of
teamwork (specific aims, type of changes initiated, degree
of participation in our QIC, time, resources, composition,
and climate) and organization (size, learning affiliation,
and culture), but our study lacks the statistical power to
justify a site-by-site analysis and only facilitates an evalua-
tion of the QIC as a general implementation strategy. The
influence of these variables therefore remained unclear.
Fifth, during the collaborative period, diabetes became a
national priority high on the public agenda and received
much attention in professional and public media.
Although the control sites remained uninvolved in orga-
nized quality improvement activities, some individual phy-
sicians or provider teams may have implemented small
changes independently. Sixth, although we include a wide
range of measures and based our measures on internation-
ally accepted indicators of diabetes care, it might be possi-
ble that improvements were made, outside the scope of
these measurements (e.g. knowledge, skills, teamwork, col-
laboration). In addition, QIC may have produced changes
in care systems that were not large enough to significantly
alter clinical processes or outcomes assessed during the
evaluation period. Finally, our quasi-experimental study
design has some limitations. Although we assessed the
outcomes in a before/after design with concurrent con-
trols, this was not a randomized trial. The participating
sites volunteered to improve their care, not to be in a trial,
so we could not randomize them to participation. Instead,
we purposely selected control sites that were comparable
to the participating sites. Although some significant base-
line differences did exist, study sites characteristics, patient
characteristics, structural aspects of diabetes care and
patient outcomes did not differ significantly at baseline.
Despite these limitations, this study represents the first
controlled evaluation of the collaborative methodology in
the Netherlands. Even though the observed difference was
modest, considering that a QIC may only be cost effective
if the results are maintained, our findings on cardiovascular
disease risk control and sustained effects of professional
performance measures at two years follow up are promis-
ing. A concomitant paper gives an extended description of
the cost effectiveness results of this trial [30].
Future research should identify collaborative, organiza-
tional and team factors associated with successful
improvement to help individual teams and organizations
increase the magnitude and pace of improvement.
Summary
Healthcare systems in the US, Canada, Australia, UK,
and northern European countries have adopted various
Table 5 Structural aspects of chronic care management
Systems of care
n = 35 clinics and practices
Baseline Short term
(one year follow up)
Long term
(two years follow up)
Assessment of Chronic Illness Care
(survey)
Intervention (SD) Control (SD) Intervention (SD) Control (SD) Intervention (SD) Control (SD)
Self-management support 6.0 (2.1) 6.9 (2.3) 7.0 (2.3) 6.4* (2.2) 6.4 (2.2) 6.2 (2.2)
Decision support 6.8 (2.1) 7.2 (2.1) 7.7 (2.2) 6.7 (1.9) 7.1 (1.6) 6.4** (2.0)
Delivery system design 7.1 (2.3) 7.8 (1.9) 7.5 (2.1) 7.8 (1.7) 7.4 (1.2) 8.0 (1.7)
Clinical information systems 6.6 (2.6) 6.4 (2.1) 6.4 (1.9) 6.1 (1.8) 7.0 (1.8) 6.7 (2.1)
Total mean 6.7 (2.1) 7.2 (1.8) 7.2 (1.9) 6.8 (1.7) 7.0 (1.4) 6.8 (1.8)
Total median 7.0 (2.5) 7.3 (2.1) 7.7 (2.5) 7.0 (1.9) 7.3 (1.6) 7.1 (2.1)
*p = 0.026 ; **p = 0.049.
Schouten et al. Implementation Science 2010, 5:94
http://www.implementationscience.com/content/5/1/94
Page 8 of 10
types of QICs. However, few rigorously controlled eva-
luations have demonstrated QIC effectiveness on out-
comes and sustained effect. We conclude that our QIC
to improve diabetes care in an integrated care setting
was associated with modest but statistically significant
long-term improvements in some patient outcomes and
significant improvement of aspects of professional per-
formance and chronic care management that were sus-
tained for at least 12 months. This suggests that gains
made in a QIC can be maintained for at least a year
without additional support or coaching.
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